Brokerages Set Context Therapeutics Inc. (NASDAQ:CNTX) Target Price at $6.00

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have been given an average rating of “Moderate Buy” by the nine brokerages that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $6.00.

Several research firms recently weighed in on CNTX. JonesTrading began coverage on shares of Context Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $7.00 target price for the company. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a research note on Thursday, November 6th. Wall Street Zen lowered shares of Context Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. HC Wainwright upped their target price on shares of Context Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Finally, Lifesci Capital upgraded shares of Context Therapeutics to a “strong-buy” rating in a research note on Monday, February 23rd.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CNTX. Millennium Management LLC bought a new stake in Context Therapeutics in the 4th quarter valued at $3,824,000. Marshall Wace LLP increased its holdings in shares of Context Therapeutics by 7,153.7% in the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after purchasing an additional 2,557,448 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Context Therapeutics by 58.8% in the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after purchasing an additional 188,202 shares during the period. Vanguard Group Inc. raised its position in shares of Context Therapeutics by 4.0% in the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock valued at $3,387,000 after purchasing an additional 134,449 shares during the period. Finally, Citadel Advisors LLC acquired a new stake in shares of Context Therapeutics during the 3rd quarter worth about $100,000. 14.03% of the stock is currently owned by institutional investors.

Context Therapeutics Stock Up 10.0%

Shares of NASDAQ:CNTX opened at $2.86 on Tuesday. The firm has a market cap of $262.78 million, a price-to-earnings ratio of -11.92 and a beta of 1.96. Context Therapeutics has a 12 month low of $0.49 and a 12 month high of $2.86. The company’s fifty day simple moving average is $2.01 and its 200 day simple moving average is $1.39.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.